Israeli researchers said they are days away from finishing production of the active component of a coronavirus vaccine that could be tested on humans starting June 1.

“We are in the final stages and within a few days we will hold the proteins—the active component of the vaccine,” Dr. Chen Katz, group leader of the biotechnology group at the MIGAL Galilee Research Institute, told The Jerusalem Post on Tuesday.

The human trials will be conducted on “young, healthy individuals” and will then likely expand to the general population, Katz said, adding that he believes the vaccine will be available first in Israel.

MIGAL said in late February that it would complete production of its vaccine within three weeks and have it on the market in three months, but Katz explained to the Post that the process was delayed because it took longer than anticipated to receive the genetic construct they ordered from China, due airways being closed and the product needing to be rerouted.

The group, funded partially by a NIS 30 million ($8,225,600) grant from Israel’s Ministry of Science and Technology, is working with regulators to ensure that the vaccine is safe to try on humans.

Katz said because it will be an oral vaccine, “the quality of this kind of vaccine should be closer to food regulations than pharma regulations or somewhere in between. We hope that we will not need to go through the complete purification process like in the drug industry because that could delay us.”

Support Jewish Journalism
with 2020 Vision

One of the most intriguing stories of the sudden Coronavirus crisis is the role of the internet. With individuals forced into home quarantine, most are turning further online for information, education and social interaction.

JNS's influence and readership are growing exponentially, and our positioning sets us apart. Most Jewish media are advocating increasingly biased progressive political and social agendas. JNS is providing more and more readers with a welcome alternative and an ideological home.

During this crisis, JNS continues working overtime. We are being relied upon to tell the story of this crisis as it affects Israel and the global Jewish community, and explain the extraordinary political developments taking place in parallel.

Our ability to thrive in 2020 and beyond depends on the generosity of committed readers and supporters. Monthly donations in particular go a long way in helping us sustain our operations. We greatly appreciate any contributions you can make during these challenging times. We thank you for your ongoing support and wish you blessings for good health and peace of mind.